GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera Inc (NAS:BFRI) » Definitions » EBITDA Margin %

BFRI (Biofrontera) EBITDA Margin % : -10.81% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biofrontera EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Biofrontera's EBITDA for the three months ended in Dec. 2024 was $-1.36 Mil. Biofrontera's Revenue for the three months ended in Dec. 2024 was $12.56 Mil. Therefore, Biofrontera's EBITDA margin for the quarter that ended in Dec. 2024 was -10.81%.


Biofrontera EBITDA Margin % Historical Data

The historical data trend for Biofrontera's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera EBITDA Margin % Chart

Biofrontera Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial -39.60 -152.52 3.26 -54.16 -38.99

Biofrontera Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.20 -110.06 8.83 -55.04 -10.81

Competitive Comparison of Biofrontera's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofrontera's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Biofrontera's EBITDA Margin % falls into.


;
;

Biofrontera EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Biofrontera's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-14.553/37.321
=-38.99 %

Biofrontera's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-1.358/12.56
=-10.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biofrontera  (NAS:BFRI) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Biofrontera EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Biofrontera's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biofrontera Business Description

Traded in Other Exchanges
N/A
Address
120 Presidential Way, Suite 330, Woburn, MA, USA, 01801
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
Executives
Heikki Lanckriet director C/O BIOFRONTERA INC., 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Eugene Frederick Leffler officer: Chief Financial Officer 84 BAY DRIVE, SUDBURY MA 01776
Kevin Daniel Weber director 119 BUCHANAN COURT, CELINA TX 75009
Borer John J Iii director 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Beth J. Hoffman director 5895 BLAZING STAR LANE, SAN DIEGO CA 92130
Loretta M. Wedge director 21260 WACISSA DRIVE, VENICE FL 34293
Ag Biofrontera 10 percent owner HEMMELRATHER WEG 201, LEVERKUSEN 2M D-51377
Erica F. Gates officer: Controller C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Erica L. Monaco director, officer: Chief Financial Officer/COO C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Hermann Luebbert director, officer: Chief Executive Officer C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801